Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Jayachandran

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
JCO Precision Oncology|April 28, 2025
Association of Androgen Receptor Expression With Tumor Immune Landscape and Treatment Outcomes of Patients With Breast CancerPriya Jayachandran, Sachin K Deshmukh, Sharon Wu, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitorsFilippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Clinical Pharmacology and Therapeutics|December 14, 2023
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentJohn D Davis, Marçal Bravo Padros, Daniela J Conrado, et al.
Journal for Immunotherapy of Cancer|November 5, 2024
Role of <i>CD47</i> gene expression in colorectal cancer: a comprehensive molecular profiling studyHiroyuki Arai, Nishant Gandhi, Francesca Battaglin, et al.
Research Square|July 10, 2026
Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancerHeinz Lenz, Hiroyuki Arai, Andrew Elliott, et al.
International Journal of Cancer|December 31, 2024
Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomesPooja Mittal, Francesca Battaglin, Yasmine Baca, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Clinical and molecular characterization of <i>AXL</i> in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world dataKaram Ashouri, Joshua Millstein, Yan Yang, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
JCO Precision Oncology|April 28, 2025
Association of Androgen Receptor Expression With Tumor Immune Landscape and Treatment Outcomes of Patients With Breast CancerPriya Jayachandran, Sachin K Deshmukh, Sharon Wu, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitorsFilippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Clinical Pharmacology and Therapeutics|December 14, 2023
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentJohn D Davis, Marçal Bravo Padros, Daniela J Conrado, et al.
Journal for Immunotherapy of Cancer|November 5, 2024
Role of <i>CD47</i> gene expression in colorectal cancer: a comprehensive molecular profiling studyHiroyuki Arai, Nishant Gandhi, Francesca Battaglin, et al.
Research Square|July 10, 2026
Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancerHeinz Lenz, Hiroyuki Arai, Andrew Elliott, et al.
International Journal of Cancer|December 31, 2024
Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomesPooja Mittal, Francesca Battaglin, Yasmine Baca, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Clinical and molecular characterization of <i>AXL</i> in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world dataKaram Ashouri, Joshua Millstein, Yan Yang, et al.
Pageof 6